Gut Microbiome Studies in Patients With POEMS Syndrome and Other Plasma Cell Disorders
Start Date
12/29/2021
Completion Date
12/29/2028
Summary
A Study to Evaluate Gut Microbiome with POEMS Syndrome and Other Plasma Cell Disorders
Detailed Description
The characteristics and role of gut microbiome rare plasma cell disorders- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) and amyloid light-chain (AL) amyloidosis, have not been explored; and their pathophysiology is quite elusive. To help understand rare plasma cell disorders and its association with gut microbiome, the investigators will study the stool samples of newly diagnosed POEMS patients and AL amyloidosis and compare it with patients with newly diagnosed monoclonal gammopathy of undetermined significance and multiple myeloma as well as healthy controls. Moreover, gut microbiome in newly diagnosed POEMS patients will be compared to POEMS patients in remission. It is the overall hypothesis that in POEMS patients the gut microbiome signature will differ between active disease (at diagnosis) and inactive disease (in remission), and the gut microbiome in POEMS patients will be different from patients with other plasma cell disorders and healthy controls.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Non-interventional study (observational)
Conditions
Locations
Mayo Clinic in Rochester
Rochester, Minnesota 55905
United States